Journal of Neurology

, Volume 253, Issue 2, pp 224–230

Metabolite changes in early relapsing–remitting multiple sclerosis

A two year follow–up study

Authors

  • M. Tiberio
    • NMR Research GroupInstitute of Neurology
    • Department of Neurological and Psychiatric SciencesUniversity of Padua
  • D. T. Chard
    • NMR Research GroupInstitute of Neurology
  • D. R. Altmann
    • NMR Research GroupInstitute of Neurology
    • Department of Medical StatisticsSchool of Hygiene and Tropical Medicine, University College London
  • G. Davies
    • NMR Research GroupInstitute of Neurology
  • C. M. Griffin
    • NMR Research GroupInstitute of Neurology
  • M. A. McLean
    • Department of Clinical and Experimental EpilepsyInstitute of Neurology, University College London
  • W. Rashid
    • NMR Research GroupInstitute of Neurology
  • J. Sastre–Garriga
    • NMR Research Unit, Department of Headache, Brain Injury and RehabilitationInstitute of Neurology, University College London
  • A. J. Thompson
    • NMR Research Unit, Department of Headache, Brain Injury and RehabilitationInstitute of Neurology, University College London
    • NMR Research GroupInstitute of Neurology
ORIGINAL COMMUNICATION

DOI: 10.1007/s00415-005-0964-z

Cite this article as:
Tiberio, M., Chard, D.T., Altmann, D.R. et al. J Neurol (2006) 253: 224. doi:10.1007/s00415-005-0964-z

Abstract

Previous in vivo proton magnetic resonance spectroscopic imaging (1H–MRSI) studies have found reduced levels of N–acetyl–aspartate (NAA) in multiple sclerosis (MS) lesions, the surrounding normal–appearing white matter (NAWM) and cortical grey matter (CGM), suggesting neuronal and axonal dysfunction and loss. Other metabolites, such as myoinositol (Ins), creatine (Cr), choline (Cho), and glutamate plus glutamine (Glx), can also be quantified by 1H–MRSI, and studies have indicated that concentrations of these metabolites may also be altered in MS. Relatively little is known about the time course of such metabolite changes. This preliminary study aimed to characterise changes in total NAA (tNAA, the sum of NAA and N–acetyl–aspartyl–glutamate), Cr, Cho, Ins and Glx concentrations in NAWM and in CGM, and their relationship with clinical outcome, in subjects with clinically early relapsing–remitting MS (RRMS). Twenty RRMS subjects and 10 healthy control subjects underwent 1H–MRSI examinations yearly for two years. Using the LCModel, tNAA, Cr, Cho, Ins and Glx concentrations were estimated both in NAWM and CGM.At baseline, the concentration of tNAA was significantly reduced in the NAWM of the MS patients compared to the control group (–7%, p = 0.003), as well as in the CGM (–8.7%, p = 0.009). NAWM tNAA concentrations tended to recover from baseline, but otherwise tissue metabolite profiles did not significantly change in the MS subjects, or relatively between MS and healthy control subjects. While neuronal and axonal damage is apparent from the early clinical stages of MS, this study suggests that initially it may be partly reversible. Compared with other MR imaging measures, serial 1H–MRSI may be relatively less sensitive to progressive pathological tissue changes in early RRMS.

Key words

multiple sclerosisearly relapsing–remittingproton magnetic resonance spectroscopic imagingbrain metabolitesaxonal damage
Download to read the full article text

Copyright information

© Steinkopff-Verlag 2005